Women at a Disadvantage in Fluorouracil Treatment-Reply.
Department of Oncologic Medicine, Gustave-Roussy, Villejuif, France2Université Paris Descartes, Paris Sorbonne Cité INSERM UMR-S775, Paris, France.
Valérie
V
Boige
Université Paris Descartes, Paris Sorbonne Cité INSERM UMR-S775, Paris, France.
Marc
M
Vincent
Université Paris Descartes, Paris Sorbonne Cité INSERM UMR-S775, Paris, France.
Pierre
P
Laurent-Puig
D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000235:genetics*; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors; D012727:Sex Characteristics
D042943:Dihydrouracil Dehydrogenase (NADP); D005472:Fluorouracil